Interventional Not yet recruiting Phase 1 Enrollment (Estimated) Enrollment 10 (Estimated)
View on ClinicalTrials.gov NCT07707986 Other Study ID: WKMU-EV-MELSAFE-001
Safety of Topical Exosome-Containing Liquid in Healthy Volunteers for Future Surgical Wound Use A Phase 1 Split-Site Pilot Study to Evaluate the Safety and Dermal Tolerability of Topical Exosome-Containing Liquid in Healthy Adult Volunteers Before Future Testing in Post-Melanoma-Excision Surgical Wounds
First Submitted: July 7, 2026
Last Update Posted: July 16, 2026
Study duration (Estimated)
4 months 2 daysStudy Start
2026-09-01
Estimated
Primary Completion
2026-12-01
Estimated
Study Completion
2027-01-01
Estimated
Study duration
4 months 2 days (Estimated)
Brief Summary
This Phase 1 split-site pilot study will evaluate the safety and dermal tolerability of a topical exosome-containing liquid in 10 healthy adult volunteers. The investigational liquid will be applied to a small defined area of intact skin. A vehicle liquid without exosomes may be applied to a matched contralateral skin site as a control. The study will assess local skin reactions, systemic adverse events, vital signs, clinical laboratory parameters, and feasibility of topical administration. No melanoma lesion, surgical wound, burn wound, or artificial skin wound will be induced in participants in this Phase 1 safety study.
Conditions
- Healthy Volunteers (HV)
- •
- Skin Irritation
Intervention / Treatment
- Biological Exosome-Containing Liquid
- Other Vehicle Liquid
Contacts and Locations
Aktobe, Aktobe
Kazakhstan, 030012
ATMP center of West Kazakhstan Marat Ospanov Medical University
Participation Criteria
|
Sexes Eligible
|
Accepts Healthy Volunteers
|
Ages Eligible
|
|---|---|---|
| ALL | Yes | 18 Years to 55 Years |
Inclusion Criteria
2. Able and willing to provide written informed consent.
3. No clinically significant abnormality based on medical history, physical examination, vital signs, and screening laboratory tests.
4. Intact healthy skin at the planned application sites.
5. Willingness to avoid applying other topical products, cosmetics, antiseptics, or irritant substances to the application sites during the study period.
6. Willingness to avoid excessive sun exposure, sauna, swimming pool use, and mechanical irritation of the application sites during the study period.
7. Willingness to comply with all study visits, topical application procedures, local skin assessments, skin photography, safety assessments, and follow-up.
8. For women of childbearing potential, a negative pregnancy test before first application and willingness to use an acceptable method of contraception during the study period.
Exclusion Criteria
2. History of severe allergy, anaphylaxis, or hypersensitivity to topical liquids, dressings, biological products, exosome-containing products, or any component of the investigational product or vehicle liquid.
3. Current acute illness, fever, or active infection.
4. Known autoimmune disease, immunodeficiency, or current systemic immunosuppressive therapy.
5. Use of systemic corticosteroids, immunomodulatory drugs, biological agents, or investigational products within 30 days before enrollment.
6. Use of topical corticosteroids, topical immunomodulators, topical antibiotics, retinoids, keratolytic agents, or other medicated topical products on or near the planned application sites within 14 days before enrollment.
7. Clinically significant hepatic, renal, cardiovascular, hematologic, endocrine, neurologic, psychiatric, or systemic disease that may increase risk or interfere with interpretation of study results.
8. Known active malignancy or history of malignancy within the past 5 years.
9. Positive screening test for clinically relevant transmissible infection, if required by the protocol.
10. Pregnancy or breastfeeding.
11. Positive pregnancy test at screening or before first application in women of childbearing potential.
12. Participation in another interventional clinical trial within 30 days before enrollment.
13. Blood donation or major blood loss within 30 days before enrollment, if laboratory safety monitoring is included in the protocol.
14. Any condition that, in the investigator's judgment, would make participation unsafe or interfere with interpretation of study results.
Participant Groups/Arms
Keywords
- exosomes
- •
- extracellular vesicles
- •
- topical exosome-containing liquid
- •
- healthy volunteers
- •
- skin tolerability
- •
- skin irritation
- •
- phase 1
- •
- first-in-human
- •
- post-melanoma-excision wound
- •
- surgical wound repair
- •
- postoperative wound healing
- •
- Dermal Tolerability
- •
- dermal safety
References
Hu JC, Zheng CX, Sui BD, Liu WJ, Jin Y. Mesenchymal stem cell-derived exosomes: A novel and potential remedy for cutaneous wound healing and regeneration. World J Stem Cells. 2022 May 26;14(5):318-329. doi: 10.4252/wjsc.v14.i5.318.
Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, Cai H, Di Vizio D, Driedonks TAP, Erdbrugger U, Falcon-Perez JM, Fu QL, Hill AF, Lenassi M, Lim SK, Mahoney MG, Mohanty S, Moller A, Nieuwland R, Ochiya T, Sahoo S, Torrecilhas AC, Zheng L, Zijlstra A, Abuelreich S, Bagabas R, Bergese P, Bridges EM, Brucale M, Burger D, Carney RP, Cocucci E, Crescitelli R, Hanser E, Harris AL, Haughey NJ, Hendrix A, Ivanov AR, Jovanovic-Talisman T, Kruh-Garcia NA, Ku'ulei-Lyn Faustino V, Kyburz D, Lasser C, Lennon KM, Lotvall J, Maddox AL, Martens-Uzunova ES, Mizenko RR, Newman LA, Ridolfi A, Rohde E, Rojalin T, Rowland A, Saftics A, Sandau US, Saugstad JA, Shekari F, Swift S, Ter-Ovanesyan D, Tosar JP, Useckaite Z, Valle F, Varga Z, van der Pol E, van Herwijnen MJC, Wauben MHM, Wehman AM, Williams S, Zendrini A, Zimmerman AJ; MISEV Consortium; Thery C, Witwer KW. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024 Feb;13(2):e12404. doi: 10.1002/jev2.12404.
Outcome Measures
|
Outcome Measure
|
Measure Description
|
Time Frame
|
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events | Number of participants with any treatment-emergent adverse event after topical application of the exosome-containing liquid. Events include local application-site reactions such as erythema, edema, pruritus, burning sensation, pain, rash, vesicles, ulceration, allergic reaction, or infection, and systemic events such as fever, malaise, abnormal vital signs, clinically significant laboratory abnormalities, serious adverse events, or any other clinically significant adverse event judged by the investigator. | From first application through Day 28 |
|
Outcome Measure
|
Measure Description
|
Time Frame
|
|---|---|---|
|
|
|
|
| Maximum Total Score on the Draize Dermal Irritation Scale at the Exosome-Containing Liquid Application Site | The Draize Dermal Irritation Scale grades erythema and eschar formation from 0, indicating no erythema, to 4, indicating severe erythema or eschar formation, and edema from 0, indicating no edema, to 4, indicating severe edema. The total score is the sum of the erythema/eschar score and edema score and ranges from 0 to 8. Higher scores indicate worse local skin irritation. The maximum total score observed at the exosome-containing liquid application site will be reported. | Baseline, 30 minutes, 24 hours, 48 hours, 72 hours, Day 7, Day 14, and Day 28 |
| Within-Participant Difference in Total Draize Dermal Irritation Scale Score Between Exosome-Containing Liquid and Vehicle-Control Sites | The within-participant difference will be calculated as the total Draize Dermal Irritation Scale score at the exosome-containing liquid application site minus the total score at the vehicle-control liquid application site at each assessment time point. The total Draize score ranges from 0 to 8, with higher scores indicating worse local skin irritation. Positive values indicate higher irritation at the exosome-containing liquid site, and negative values indicate higher irritation at the vehicle-control site. | Baseline, 30 minutes, 24 hours, 48 hours, 72 hours, Day 7, Day 14, and Day 28 |
| Number of Participants With Clinically Significant Vital Sign Abnormalities | Number of participants with any clinically significant abnormality in vital signs after topical application of the exosome-containing liquid. Vital signs include systolic blood pressure, diastolic blood pressure, heart rate, respiratory rate, and body temperature. Clinical significance will be determined by the investigator using protocol-defined reference ranges and clinical judgment. The reporting unit is number of participants. | From first application through Day 28 |
| Number of Participants With Clinically Significant Clinical Laboratory Abnormalities | Number of participants with any clinically significant abnormality in clinical laboratory safety tests after topical application of the exosome-containing liquid. Laboratory safety tests include complete blood count, renal function tests, liver function tests, and inflammatory markers according to the protocol. Clinical significance will be determined by the investigator using protocol-defined reference ranges and clinical judgment. The reporting unit is number of participants. | From first application through Day 28 |
| Percentage of Planned Topical Applications Completed According to Protocol | For each participant, the topical application completion percentage will be calculated as the number of completed topical applications divided by the number of protocol-planned topical applications, multiplied by 100. The outcome will be reported as the mean percentage of planned topical applications completed across participants. A higher percentage indicates better feasibility of topical application. | From Day 0 through Day 7 or Day 14, according to the protocol-defined application schedule |
| Number of Participants With Delayed Treatment-Emergent Adverse Events | Number of participants with delayed local or systemic treatment-emergent adverse events occurring after completion of the primary Day 28 safety assessment. Delayed events may include local skin reactions, allergic reactions, infection, abnormal vital signs, clinically significant laboratory abnormalities, serious adverse events, or any other clinically significant adverse event judged by the investigator. | From Day 29 through Day 56 |